Thomas Heath, M.B.A. is the President and CEO of GlycoMira Therapeutics. Before joining GlycoMira, Tom Heath served as Senior Vice President at NPS Pharmaceutials. He was a Founder-Director-President at Echelon Biosciences and also was Pharmaceutical Division Manager at Pfizer (Montreal, Canada). Mr. Heath received his MBA from the David Eccles School of Business at the University of Utah.

A co-founder of GlycoMira Therapeutics, Dr. Glenn Prestwich, Ph.D. is Presidential Professor of Medicinal Chemistry and Presidential Special Assistant for Faculty Entrepreneurism at the University of Utah. Dr. Prestwich’s research interests are hyaluronan derivatives for tissue engineering and reparative medicine, lipid signaling, and anti-inflammatory therapeutic compounds. He has received numerous awards for his contributions to science and tec

A co-founder of GlycoMira Therapeutics, Dr. Tom Kennedy, M.D. is a Professor of Medicine at Georgia Regents University School of Medicine. Dr. Kennedy’s research interests are biomedical applications of heparinoid compounds to treat human diseases. He is one of our major driving forces in research and development.
Previously, Dr. Kennedy was Professor of Medicine at the University of Utah. He received his medical training at Vanderbilt

Justin R. Savage, Ph.D. is Director of Operations for GlycoMira Therapeutics, Inc. and has been with the Company since 2009. Dr. Savage has over 10 years of experience in proteomics and drug development.
Dr. Savage received his B.A. degree in chemistry from Southern Utah University and his Ph.D. in Biochemistry from Brigham Young University.